Home › NCT06220864

SNV1521 in Participants With Advanced Solid Tumors

A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Advanced or metastatic solid tumor malignancy
* Evaluable or Measurable disease (RECIST 1.1 Criteria).
* ECOG Performance Status 0 or 1.
* Life expectancy \> 3 months

Exclusion Criteria:

* History of other malignancy within the past 2 years
* Prior diagnosis of Myelodysplastic syndrome or Acute Myeloid Leukemia
* Significant cardiovascular disease within 6 months
* Significant gastrointestinal disease
* HIV infection with a CD4+ T-cell count \< 200 cells/μL and/or a detectable viral load
* Liver dysfunction

About the study

This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.

What is being tested

• SNV1521 (drug)
• DB-1310 (drug)
• Abiraterone (drug)
• Darolutamide (drug)

Sponsor: Synnovation Therapeutics, Inc. · Participants: 400 · Started: Feb 23, 2024

Contact the study team

• Robert Casper · Phone: 443-764-9527

Official record on ClinicalTrials.gov — NCT06220864

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.